Core Insights - Aclarion has been added to the PRISM Emerging Medical Devices Index, highlighting its innovative position in the medtech sector with its AI-driven diagnostic solutions for chronic low back pain [1][3] - The U.S. medical devices market is projected to grow to nearly 315 billion by 2032, driven by increased R&D investments and innovations like Aclarion's NOCISCAN technology [1][2] Company Highlights - Aclarion's NOCISCAN technology is the first noninvasive diagnostic tool for identifying painful discs in patients with chronic low back pain, improving surgical outcomes [3][4] - The company addresses a significant healthcare expenditure, with the lumbar spine diagnostics and treatment market estimated at 40 billion annually, contributing to overall costs of up to $134.5 billion [2][3] - Aclarion has secured its first commercial agreement with Sheridan Community Hospital in Michigan and extended its agreement with The London Clinic, increasing access to its technology [3][4] - The company has obtained private payer coverage from major UK insurers, covering 60% of private health insurance patients in greater London [3] - Aclarion's technology is supported by strong clinical data, showing an 85% improvement in patients treated based on NOCISCAN diagnostics, with ongoing clinical trials to further validate its efficacy [3][4] Industry Context - The medical devices market is experiencing significant growth, with a robust pipeline of innovations and increasing investments in research and development [1][2] - Chronic low back pain is a major health challenge affecting 266 million patients globally, highlighting the demand for effective diagnostic and treatment solutions [3]
Aclarion Added to PRISM Emerging Medical Devices Index